Atossa Genetics (ATOS) and The Competition Head to Head Review

Atossa Genetics (NASDAQ: ATOS) is one of 121 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it compare to its rivals? We will compare Atossa Genetics to similar companies based on the strength of its analyst recommendations, institutional ownership, risk, earnings, valuation, dividends and profitability.

Profitability

This table compares Atossa Genetics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Atossa Genetics N/A -172.50% -94.42%
Atossa Genetics Competitors -30.00% -41.48% -13.59%

Earnings and Valuation

This table compares Atossa Genetics and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Atossa Genetics N/A -$11.40 million -0.49
Atossa Genetics Competitors $1.48 billion $146.48 million 42.19

Atossa Genetics’ rivals have higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Atossa Genetics has a beta of 3.79, suggesting that its share price is 279% more volatile than the S&P 500. Comparatively, Atossa Genetics’ rivals have a beta of 1.13, suggesting that their average share price is 13% more volatile than the S&P 500.

Insider & Institutional Ownership

8.6% of Atossa Genetics shares are owned by institutional investors. Comparatively, 50.6% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 3.1% of Atossa Genetics shares are owned by insiders. Comparatively, 15.9% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Atossa Genetics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atossa Genetics 0 0 2 0 3.00
Atossa Genetics Competitors 804 2807 4982 252 2.53

Atossa Genetics currently has a consensus price target of $9.50, indicating a potential upside of 255.81%. As a group, “Surgical & medical instruments” companies have a potential upside of 23.82%. Given Atossa Genetics’ stronger consensus rating and higher possible upside, research analysts plainly believe Atossa Genetics is more favorable than its rivals.

Summary

Atossa Genetics rivals beat Atossa Genetics on 8 of the 13 factors compared.

About Atossa Genetics

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit